Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients

European Journal of Clinical Pharmacology

Volumn 65, Issue 11, 2009, Pages 1097-1103

  Ohno, Masako ^a   Yamamoto, Akiko ^a   Ono, Ayumu ^b   Miura, Genta ^c   Funamoto, Masanobu ^d   Takemoto, Yasuhiko ^e   Otsu, Kinya ^f   Kouno, Yasushi ^e   Tanabe, Tomoko ^a   Masunaga, Yuiko ^a   Nonen, Shinpei ^a   Fujio, Yasushi ^a   Azuma, Junichi ^a,g  

^a OSAKA UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c Otsuki Hospital   (Japan)

^d Himeshima National Health Insurance Clinic   (Japan)

^e Funamoto Clinic   (Japan)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Algorithm; CYP2C9; Genetic polymorphism; VKORC1; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 7; CYTOCHROME P450 2C9; MENADIONE EPOXIDE; MENADIONE EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; VITAMIN K DEPENDENT CARBOXYLASE; WARFARIN;

ADULT; AGED; ARTICLE; BODY SURFACE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; JAPANESE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CARBON-CARBON LIGASES; FACTOR VII; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; WARFARIN;

EID: 70350706287     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0685-9     Document Type: Article

References (32)

1. FDA (2007) FDA approves updated warfarin (Coumadin) prescribing information. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html.
2. CR Lee JA Goldstein JA Pieper 2002 Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data Pharmacogenetics 12 251 263 10.1097/00008571-200204000-00010 1:CAS:528:DC%2BD38XnsFKqsLc%3D 11927841 (Pubitemid 34596790)
3. LS Kaminsky ZY Zhang 1997 Human P450 metabolism of warfarin Pharmacol Ther 73 67 74 10.1016/S0163-7258(96)00140-4 1:CAS:528:DyaK28Xns1Cjsrw%3D 9014207 (Pubitemid 26425815)
4. Human Cytochrome P450 (CYP) Allele Nomenclature Committee (2008) Allele nomenclature for Cytochrome P450 enzymes. http://www.imm.ki.se/CYPalleles/
5. M Kimura I Ieiri K Mamiya, et al. 1998 Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population Ther Drug Monit 20 243 247 10.1097/00007691-199806000-00001 1:CAS:528:DyaK1cXjvVChs7k%3D 9631918 (Pubitemid 28248841)
6. H Takahashi H Echizen 2003 Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin Pharmacogenomics J 3 202 214 10.1038/sj.tpj.6500182 1:CAS:528:DC%2BD3sXmsFWisrY%3D 12931134 (Pubitemid 37167925)
7. J Kirchheiner J Brockmöller 2005 Clinical consequences of cytochrome P450 2C9 polymorphisms Clin Pharmacol Ther 77 1 16 10.1016/j.clpt.2004.08.009 1:CAS:528:DC%2BD2MXks1Wh 15637526 (Pubitemid 40089477)
8. GP Aithal CP Say PJL Kesteven, et al. 1999 Association of polymorphisms in cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 717 719 10.1016/S0140-6736(98)04474-2 1:STN:280:DyaK1M7ntFGhsQ%3D%3D 10073515 (Pubitemid 29103806)
9. MS Ogg P Brennan T Meade, et al. 1999 CYP2C9*3 allelic variant and bleeding complications Lancet 354 1124 10.1016/S0140-6736(05)76918-X 1:STN:280:DyaK1Mvjslahuw%3D%3D 10509530
10. M Margaglione D Colaizzo G D'Andrea, et al. 2000 Genetic modulation of oral anticoagulation with warfarin Thromb Haemost 84 775 778 1:CAS:528:DC%2BD3cXovFCjs7g%3D 11127854
11. MK Higashi DL Veenstra LM Kondo, et al. 2002 Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 1690 1698 10.1001/jama.287.13.1690 1:CAS:528:DC%2BD38XisFaru7c%3D 11926893
12. K Obayashi K Nakamura J Kawana, et al. 2006 VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients Clin Pharmacol Ther 80 169 178 10.1016/j.clpt.2006.04.010 1:CAS:528: DC%2BD28XotFKhtrY%3D 16890578 (Pubitemid 44160690)
13. HY Yuan JJ Chen M Lee MT, et al. 2005 A novel functional VKORC1 promoter polymorphism in associated with inter-individual and inter-ethnic differences in warfarin sensitivity Hum Mol Genet 14 1745 1751 10.1093/hmg/ddi180 1:CAS:528:DC%2BD2MXmvV2htL0%3D 15888487 (Pubitemid 41430097)
14. T Mushiroda Y Ohnishi S Saito, et al. 2006 Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients J Him Genet 51 249 253 10.1007/s10038-005-0354-5 1:CAS:528:DC%2BD28Xis1Oktrc%3D
15. UI Schwartz CM Stein 2006 Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants Clin Pharmacol Ther 80 7 12 10.1016/j.clpt.2006.04.008 (Pubitemid 43946847)
16. E Shikata I Ieiri S Ishiguro, et al. 2004 Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity Blood 103 2630 2635 10.1182/blood-2003-09-3043 1:CAS:528:DC%2BD2cXjtVaks7o%3D 14656880 (Pubitemid 38393017)
17. D Herman P Peternel M Stegnar, et al. 2006 The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement Thromb Haemost 95 782 787 1:CAS:528:DC%2BD28Xlt1WgtLc%3D 16676068
18. R Kimura K Miyashita Y Kokubo, et al. 2007 Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients Thromb Res 120 181 186 10.1016/j.thromres.2006.09.007 1:CAS:528:DC%2BD2sXlsFKgsbw%3D 17049586 (Pubitemid 46754413)
19. CL Aquilante TY Langaee LM Lopez, et al. 2006 Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements Clin Pharmacol Ther 79 291 302 10.1016/j.clpt.2005.11.011 1:CAS:528:DC%2BD28XjtFaiur4%3D 16580898
20. FM Van't Hooft A Silveira P Tornvall, et al. 1999 Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration Blood 93 3432 3441 (Pubitemid 29220910)
21. C Bozzini D Girelli F Bernardi, et al. 2004 Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis Thromb Haemost 92 541 549 1:CAS:528:DC%2BD2cXnvFyhtLg%3D 15351850
22. K Ito K Goto T Sugiura 2007 Polymorphisms of the factor VII gene associated with the low activities of vitamin K-dependent coagulation factors in one-month-old infants Tohoku J Exp Med 211 1 8 10.1620/tjem.211.1 1:CAS:528:DC%2BD2sXhsFymsLg%3D 17202767 (Pubitemid 46062214)
23. T Fukuda T Tanabe M Ohno, et al. 2006 Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes Clin Pharmacol Ther 80 553 554 10.1016/j.clpt.2006.08.005 1:CAS:528: DC%2BD28Xht1elsrfJ 17112813 (Pubitemid 44737485)
24. D DuBois E DuBois 1916 Clinical calorimetry; a formula to estimate the approximate surface area if height and weight be known Arch Int Med 17 863 871 1:CAS:528:DyaC28XhtVCnug%3D%3D
25. The Japanese Circulation Society 2008 Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008) Circ J 72 1581 1638
26. T Yamaguchi 2000 Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group Stroke 31 817 821 1:CAS:528:DC%2BD3cXivFajt7s%3D 10753981
27. JF Carlquist BD Horne JB Muhlestein, et al. 2006 Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study J Thromb Thrombolysis 22 191 197 10.1007/s11239-006-9030-7 1:CAS:528: DC%2BD28Xht1yis7vM 17111199 (Pubitemid 44857780)
28. MD Caldwell RL Berg KQ Zhang, et al. 2007 Evaluation of genetic factors for warfarin dose prediction Clin Med Res 5 8 16 10.3121/cmr.2007.724 1:CAS:528:DC%2BD2sXhtFClu7vL 17456829 (Pubitemid 350218774)
29. Y Zhu M Shennan KK Reynolds, et al. 2007 Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes Clin Chem 53 1199 1205 10.1373/clinchem.2006.078139 1:CAS:528:DC%2BD2sXntlCqsLc%3D 17510308 (Pubitemid 47020974)
30. L Miao J Yang C Huang, et al. 2007 Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients Eur J Clin Pharmacol 63 1135 1141 10.1007/s00228-007-0381-6 1:CAS:528:DC%2BD2sXht1yit7zM 17899045 (Pubitemid 350112769)
31. JL Anderson BD Horne SM Stevens, et al. 2007 Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 2563 2570 10.1161/CIRCULATIONAHA.107.737312 1:CAS:528:DC%2BD2sXhtlagsb3F 17989110 (Pubitemid 350179221)
32. V Fuster LE Rydén DS Cannom, et al. 2006 ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 e257 354 10.1161/CIRCULATIONAHA.106.177292 16908781 (Pubitemid 44252297)